drugset / Trial / NCT00317174

A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.

NCT00317174 ↗

Phase 2 Completed 450 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is as follows: * To evaluate the persistence of antibodies and the presence of immune memory induced by a 3-dose primary vaccination with Tritanrix™-HepB/Hib-MenAC (three formulations) in the study DTPwHB/HibMenACTT001 (CPMS No. 759346/001) by giving unconjugated PRP, PSA and PSC at 10 months age to one subset of subjects. * To evaluate the persistence of all antibodies pertaining to primary vaccination and the booster response to Tritanrix™-HepB/Hib2.5 vaccine or Tritanrix™-HepB/Hib-MenAC vaccine at 15-18 months age in the other subset of subjects.

Timeline

Start
2003-07
Primary completion
—
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject DTPw-HBV/Hib-MenAC conjugate vaccine Vaccine — —